TRAFO/LT

Translationale Forschung (TRAFO) und Forschung zur Lokaltherapie (LT)

Forschungsinteressen für translationale Forschung bei der WSG

Die Forschungsinteressen der WSG GmbH umfassen mehrere Bereiche. Für die translationale Forschung an Gewebeproben und Blutproben, die an Patient:innen während der klinischen Studien der WSG erhoben werden, umfasst dies folgende Bereiche:

Blutbasierte Methoden
RNA, DNA
gewebebasierte Methoden

Forschungsinteressen zur Lokaltherapie bei der WSG

Darüber hinaus verfolgt die WSG GmbH neben Forschungsfragestellungen zur deeskalierenden Systemtherapie auch lokaltherapeutische Fragestellungen, welche sich über die folgenden Bereiche erstrecken:

Chirurgie
Strahlentherapie
Bildgebung

Interesse an einer TRAFO/LT-Kooperation mit der WSG?

Für den Fall, dass eine TRAFO-Kooperation mit der WSG angestrebt wird, können entsprechende Proposal-Vorlagen genutzt werden.

Dokumentendownload TRAFO-Proposal

Dokumentendownload Lokaltherapie-Proposal

Bitte senden Sie das ausgefüllte Formular an: verena.stehl@wsg-online.com

Auszug aus den bisherigen TRAFO-Publikationen der WSG

Im Folgenden wird ein Auszug aus den bisherigen TRAFO-Publikationen der WSG präsentiert. Darüber hinaus existieren zahlreiche weitere Publikationen.

Korbie, D., Stirzaker, C., Gluz, O. et al. Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial. Mol Cancer 24, 96 (2025). https://doi.org/10.1186/s12943-025-02275-0
Graeser, M., Gluz, O., Biehl, C., Ulbrich-Gebauer, D., Christgen, M., Palatty, J., Kuemmel, S., Grischke, E. M., Augustin, D., Braun, M., Potenberg, J., Wuerstlein, R., Krauss, K., Schumacher, C., Forstbauer, H., Reimer, T., Stefek, A., Fischer, H. H., Pelz, E., Zu Eulenburg, C., … Harbeck, N. (2023). Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(4), 805–814. https://doi.org/10.1158/1078-0432.CCR-22-1587
Graeser, M., Schrading, S., Gluz, O., Strobel, K., Herzog, C., Umutlu, L., Frydrychowicz, A., Rjosk-Dendorfer, D., Würstlein, R., Culemann, R., Eulenburg, C., Adams, J., Nitzsche, H., Prange, A., Kümmel, S., Grischke, E. M., Forstbauer, H., Braun, M., Potenberg, J., von Schumann, R., … Nitz, U. (2021). Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials. Breast cancer research : BCR, 23(1), 36. https://doi.org/10.1186/s13058-021-01413-y
Graeser, M., Feuerhake, F., Gluz, O., Volk, V., Hauptmann, M., Jozwiak, K., Christgen, M., Kuemmel, S., Grischke, E. M., Forstbauer, H., Braun, M., Warm, M., Hackmann, J., Uleer, C., Aktas, B., Schumacher, C., Kolberg-Liedtke, C., Kates, R., Wuerstlein, R., Nitz, U., … Harbeck, N. (2021). Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. Journal for immunotherapy of cancer, 9(5), e002198. https://doi.org/10.1136/jitc-2020-002198
Graeser, M., Schrading, S., Gluz, O., Strobel, K., Würstlein, R., Kümmel, S., Schumacher, C., Grischke, E. M., Forstbauer, H., Braun, M., Christgen, M., Adams, J., Nitzsche, H., Just, M., Fischer, H. H., Aktas, B., Potenberg, J., von Schumann, R., Kolberg-Liedtke, C., Harbeck, N., … Nitz, U. (2021). Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials. International journal of cancer, 148(10), 2614–2627. https://doi.org/10.1002/ijc.33495
Graeser, M., Harbeck, N., Gluz, O., Würstlein, R., Zu Eulenburg, C., Schumacher, C., Grischke, E. M., Forstbauer, H., Dimpfl, M., Braun, M., Christgen, M., Kreipe, H. H., Potenberg, J., von Schumann, R., Aktas, B., Kolberg-Liedtke, C., Kümmel, S., & Nitz, U. (2021). The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. Breast (Edinburgh, Scotland), 59, 58–66. https://doi.org/10.1016/j.breast.2021.06.001
Christgen, M., Steinemann, D., Kühnle, E., Länger, F., Gluz, O., Harbeck, N., & Kreipe, H. (2016). Lobular breast cancer: Clinical, molecular and morphological characteristics. Pathology, research and practice, 212(7), 583–597. https://doi.org/10.1016/j.prp.2016.05.002
Christgen, M., Bartels, S., Radner, M., Raap, M., Rieger, L., Christgen, H., Gluz, O., Nitz, U., Harbeck, N., Lehmann, U., & Kreipe, H. (2019). ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling. Genes, chromosomes & cancer, 58(3), 175–185. https://doi.org/10.1002/gcc.22716
Christgen, M., Kandt, L. D., Antonopoulos, W., Bartels, S., Van Bockstal, M. R., Bredt, M., Brito, M. J., Christgen, H., Colpaert, C., Cserni, B., Cserni, G., Daemmrich, M. E., Danebrock, R., Dedeurwaerdere, F., van Deurzen, C. H., Erber, R., Fathke, C., Feist, H., Fiche, M., Gonzalez, C. A., … Kreipe, H. (2022). Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma. The journal of pathology. Clinical research, 8(2), 191–205. https://doi.org/10.1002/cjp2.253
Gluz, O., Liedtke, C., Huober, J., Peyro-Saint-Paul, H., Kates, R. E., Kreipe, H. H., Hartmann, A., Pelz, E., Erber, R., Mohrmann, S., Möbus, V., Augustin, D., Hoffmann, G., Thomssen, C., Jänicke, F., Kiechle, M., Wallwiener, D., Kuhn, W., Nitz, U., & Harbeck, N. (2016). Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Annals of oncology : official journal of the European Society for Medical Oncology, 27(6), 1035–1040. https://doi.org/10.1093/annonc/mdw070

Translational Research (TRAFO) and Research on Local Therapy (LT)

Research interests for translational research at WSG

The research interests of WSG GmbH cover several areas. For translational research on tissue samples and blood samples collected from patients during WSG clinical trials, this includes the following areas:

Blood-based methods
RNA, DNA
Tissue-based methods

Research interests on local therapy at WSG

In addition to research questions on the de-escalation of systemic therapy, WSG GmbH is also addressing local therapeutic questions in the following areas:

Surgery
Radiotherapy
Imaging

Interested in a TRAFO cooperation with the WSG?

If you are interested in a TRAFO cooperation with the WSG, you can use the corresponding proposal templates.

Document download TRAFO-Proposal

Document download Local Therapy Imaging-Proposal

Please send the completed form to: verena.stehl@wsg-online.com

Extract from the WSG's previous TRAFO publications

The following is an excerpt from the WSG's previous TRAFO publications. Numerous other publications are available.

Korbie, D., Stirzaker, C., Gluz, O. et al. Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial. Mol Cancer 24, 96 (2025). https://doi.org/10.1186/s12943-025-02275-0
Graeser, M., Gluz, O., Biehl, C., Ulbrich-Gebauer, D., Christgen, M., Palatty, J., Kuemmel, S., Grischke, E. M., Augustin, D., Braun, M., Potenberg, J., Wuerstlein, R., Krauss, K., Schumacher, C., Forstbauer, H., Reimer, T., Stefek, A., Fischer, H. H., Pelz, E., Zu Eulenburg, C., … Harbeck, N. (2023). Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(4), 805–814. https://doi.org/10.1158/1078-0432.CCR-22-1587
Graeser, M., Schrading, S., Gluz, O., Strobel, K., Herzog, C., Umutlu, L., Frydrychowicz, A., Rjosk-Dendorfer, D., Würstlein, R., Culemann, R., Eulenburg, C., Adams, J., Nitzsche, H., Prange, A., Kümmel, S., Grischke, E. M., Forstbauer, H., Braun, M., Potenberg, J., von Schumann, R., … Nitz, U. (2021). Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials. Breast cancer research : BCR, 23(1), 36. https://doi.org/10.1186/s13058-021-01413-y
Graeser, M., Feuerhake, F., Gluz, O., Volk, V., Hauptmann, M., Jozwiak, K., Christgen, M., Kuemmel, S., Grischke, E. M., Forstbauer, H., Braun, M., Warm, M., Hackmann, J., Uleer, C., Aktas, B., Schumacher, C., Kolberg-Liedtke, C., Kates, R., Wuerstlein, R., Nitz, U., … Harbeck, N. (2021). Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. Journal for immunotherapy of cancer, 9(5), e002198. https://doi.org/10.1136/jitc-2020-002198
Graeser, M., Schrading, S., Gluz, O., Strobel, K., Würstlein, R., Kümmel, S., Schumacher, C., Grischke, E. M., Forstbauer, H., Braun, M., Christgen, M., Adams, J., Nitzsche, H., Just, M., Fischer, H. H., Aktas, B., Potenberg, J., von Schumann, R., Kolberg-Liedtke, C., Harbeck, N., … Nitz, U. (2021). Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials. International journal of cancer, 148(10), 2614–2627. https://doi.org/10.1002/ijc.33495
Graeser, M., Harbeck, N., Gluz, O., Würstlein, R., Zu Eulenburg, C., Schumacher, C., Grischke, E. M., Forstbauer, H., Dimpfl, M., Braun, M., Christgen, M., Kreipe, H. H., Potenberg, J., von Schumann, R., Aktas, B., Kolberg-Liedtke, C., Kümmel, S., & Nitz, U. (2021). The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. Breast (Edinburgh, Scotland), 59, 58–66. https://doi.org/10.1016/j.breast.2021.06.001
Christgen, M., Steinemann, D., Kühnle, E., Länger, F., Gluz, O., Harbeck, N., & Kreipe, H. (2016). Lobular breast cancer: Clinical, molecular and morphological characteristics. Pathology, research and practice, 212(7), 583–597. https://doi.org/10.1016/j.prp.2016.05.002
Christgen, M., Bartels, S., Radner, M., Raap, M., Rieger, L., Christgen, H., Gluz, O., Nitz, U., Harbeck, N., Lehmann, U., & Kreipe, H. (2019). ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling. Genes, chromosomes & cancer, 58(3), 175–185. https://doi.org/10.1002/gcc.22716
Christgen, M., Kandt, L. D., Antonopoulos, W., Bartels, S., Van Bockstal, M. R., Bredt, M., Brito, M. J., Christgen, H., Colpaert, C., Cserni, B., Cserni, G., Daemmrich, M. E., Danebrock, R., Dedeurwaerdere, F., van Deurzen, C. H., Erber, R., Fathke, C., Feist, H., Fiche, M., Gonzalez, C. A., … Kreipe, H. (2022). Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma. The journal of pathology. Clinical research, 8(2), 191–205. https://doi.org/10.1002/cjp2.253
Gluz, O., Liedtke, C., Huober, J., Peyro-Saint-Paul, H., Kates, R. E., Kreipe, H. H., Hartmann, A., Pelz, E., Erber, R., Mohrmann, S., Möbus, V., Augustin, D., Hoffmann, G., Thomssen, C., Jänicke, F., Kiechle, M., Wallwiener, D., Kuhn, W., Nitz, U., & Harbeck, N. (2016). Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Annals of oncology : official journal of the European Society for Medical Oncology, 27(6), 1035–1040. https://doi.org/10.1093/annonc/mdw070